IRAKLIA Data Support Subcutaneous Isatuximab as a SOC Administration Approach in Myeloma
Addition of Dasatinib to Induction/Consolidation Fails to Boost Survival in Core-Binding Factor AML
Talquetamab/Cetrelimab Leads to Deep, Durable Responses in R/R Multiple Myeloma
Dr Curtis on Cyclophosphamide GVHD Prophylaxis in Matched Donor Transplant